UCB Canada
- Company typePrivate
- Founded2006
- HeadquartersBelleville, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
UCB Canada firmographics
Firmographics- Name
- UCB Canada
- Legal name
- UCB Canada Inc.
- Website
- https://ucbcanada.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
UCB Canada industry classification
Industry- Product category
- Biopharmaceutical Medicines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where UCB Canada is headquartered
LocationHeadquarters
- HQ city
- Belleville
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
UCB Canada business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Others
Revenue model
- Pharmaceutical product sales: UCB Canada generates revenue through the sale of prescription biopharmaceutical medicines for immunology, neurology, and rare disease conditions. Products are distributed through pharmacy channels and reimbursed via public drug plans, private insurance, Veterans Affairs Canada, and the Non-Insured Health Benefits Program. The company negotiates with the pan-Canadian Pharmaceutical Alliance (pCPA) and provincial formularies for public reimbursement coverage.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
UCB Canada product offering
Product offeringCore offering
UCB Canada develops, manufactures, and commercializes prescription biopharmaceutical medicines in Canada, focused on immunology (psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, hidradenitis suppurativa, rheumatoid arthritis), neurology (epilepsy, Parkinson's disease), and rare diseases (generalized myasthenia gravis). The company also operates patient support programs (UCB Cares, UCB Connects, RxHelp ONE, ONWARD) and the FASTRAX Canada diagnostic innovation program for axial spondyloarthritis.
Product overview
UCB Canada is a biopharmaceutical company offering a portfolio of prescription medications primarily focused on immunology, neurology, and rare diseases. The core product portfolio includes BIMZELX® (bimekizumab injection) for psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and hidradenitis suppurativa; CIMZIA® (certolizumab pegol) for rheumatoid arthritis; BRIVLERA® (brivaracetam), KEPPRA® (levetiracetam), VIMPAT® (lacosamide), and NEUPRO® (rotigotine) for epilepsy and neurological conditions; and RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan) for generalized myasthenia gravis. Complementing the medication portfolio are patient support programs including UCB Cares™ for CIMZIA® and BIMZELX® patients, UCB Connects for BRIVLERA® and NEUPRO® patients, RxHelp ONE for BRIVLERA® and VIMPAT® patients, and ONWARD™ for rare disease patients. The FASTRAX Canada program provides diagnostic support for axial spondyloarthritis.
Differentiator
Problem solved
Functional benefit
Brands
- UCBCares®: Patient support programs for patients prescribed UCB medicines, covering immunology and neurology conditions.
- FASTRAX
Products and services
- BIMZELX (bimekizumab injection) Monoclonal antibody IL-17A and IL-17F inhibitor approved in Canada for moderate to severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis, and moderate to severe hidradenitis suppurativa. Prescribed by dermatologists and rheumatologists.
- CIMZIA (certolizumab pegol) Tumor necrosis factor (TNF) inhibitor injection indicated for rheumatoid arthritis and other inflammatory conditions.
- BRIVLERA (brivaracetam)
- KEPPRA (levetiracetam)
- VIMPAT (lacosamide)
- NEUPRO (rotigotine transdermal patch)
- RYSTIGGO (rozanolixizumab injection)
- ZILBRYSQ (zilucoplan injection)
- FASTRAX Canada
- UCB Cares Patient Support Program
- UCB Connects
- RxHelp ONE
- ONWARD Patient Support Program
- UCBeyond Scholarship Program
Quantifiable outcome
- BIMZELX (bimekizumab) demonstrated statistically significant HiSCR50 response at Week 16 vs. placebo in BE HEARD I and II Phase III trials enrolling 1,014 patients globally.
- +4 more outcomes
Companies that use UCB Canada
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
UCB Canada technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
UCB Canada partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core and minor.
- Canada's Drug Agency (CDA-AMC)coreCDA-AMC issued a positive reimbursement recommendation with conditions for BIMZELX (bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa. This recommendation reflects clinical evidence submitted, patient and clinician input, and significant unmet need.
- Groupe de recherche en rhumatologie et maladies osseuses (GRMO) — Quebec City cliniccoreUCB Canada expanded its FASTRAX Canada program to Quebec City in partnership with GRMO (Groupe de recherche en rhumatologie et maladies osseuses). This site contributes to national perspectives from diverse referral contexts and strengthens the Canadian clinical database supporting early identification and diagnosis of inflammatory back pain. The program involves rheumatologists and Advanced Clinician Practitioners in Arthritis Care (ACPAC) to accelerate axSpA diagnosis in Eastern Canada.
- INESSS (Quebec's health technology assessment body)coreINESSS issued a positive reimbursement recommendation for PrBIMZELX (bimekizumab injection) for adults with moderate to severe hidradenitis suppurativa who have inadequate response to conventional systemic therapy. This is the fifth indication for BIMZELX in Canada and is conditional on economic requirements being met.
- Thunder Bay Rheumatology CliniccoreUCB expanded its FASTRAX Canada program by opening a site at the Thunder Bay Rheumatology Clinic to improve diagnosis and care for axSpA patients in Northwestern Ontario. This expansion aims to address healthcare disparities, increase access to specialized care, and reduce diagnosis delays for an estimated 855,000 residents, including Indigenous populations.
- pan-Canadian Pharmaceutical Alliance (pCPA)coreThe pCPA successfully concluded negotiations for PrZILBRYSQ (zilucoplan) and PrRYSTIGGO (rozanolixizumab), marking a necessary step for securing provincial public reimbursement and increased access for Canadians living with generalized myasthenia gravis (gMG).
- Université de Toronto / Dr. Hans KatzbergminorDr. Hans Katzberg, Professor of Medicine at the University of Toronto, has publicly supported public reimbursement of rozanolixizumab and zilucoplan, noting the clinical benefits of subcutaneous therapies for gMG patients.
- University Health Network (UHN) — TorontocoreUHN Toronto served as the founding site for FASTRAX Canada. The axSpA screening clinic model designed and led by an interprofessional rheumatology team at UHN served as the foundation for FASTRAX expansion across Ontario and beyond. Data from the UHN FASTRAX study showed approximately 22% of patients who completed the FASTRAX pathway received a confirmed axSpA diagnosis.
- L'Hôpital d'Ottawa (TOH)coreFASTRAX Canada site at L'Hôpital d'Ottawa (TOH) addresses high volumes of specialist referrals in Eastern Ontario and contributes to the provincial strategy for transforming axSpA access and care.
- Advanced Clinician Practitioners in Arthritis Care (ACPAC)coreACPAC practitioners are highly qualified physiotherapists authorized to perform diagnostic evaluations in accordance with medical directives. They collaborate closely with rheumatologists within the FASTRAX program, using their advanced scope of practice to request MRI exams and blood tests, increasing clinical capacity in rheumatology by accelerating triage and testing.
- Canadian Spondylitis AssociationminorUCB Canada supports the Canadian Spondylitis Association's Lace Up for axSpA campaign during spondylitis awareness month, raising awareness of axSpA challenges and the need for faster diagnosis across Canadian communities.
- Muscular Dystrophy CanadaminorMuscular Dystrophy Canada advocates for people living with gMG and supports increased access to innovative therapies. The organization emphasizes timely access to treatments and encourages provinces to act quickly with listings to ensure patients across Canada can benefit equally.
- Canadian Dermatology Patient Association (ACPD / Alliance canadienne des patients en dermatologie)minorThe ACPD is committed to advocating for the needs of people living with hidradenitis suppurativa and ensuring their voice is heard in decisions that influence access to care. The association emphasizes the need for equitable and timely access to appropriate treatment options.
- Hidradenitis & Me Support GroupminorPatient-founded support group for people living with hidradenitis suppurativa. Founder Latoya Palmer has spoken publicly about the impact of new HS treatments and the importance of patient access to innovative therapies.
- Veterans Affairs CanadacoreFederal government program providing public reimbursement coverage for RYSTIGGO (rozanolixizumab) and ZILBRYSQ (zilucoplan) for eligible Canadian veterans.
- Non-Insured Health Benefits Program (NIHB)coreFederal Indigenous health coverage program providing public reimbursement for RYSTIGGO (rozanolixizumab) and ZILBRYSQ (zilucoplan) for eligible Indigenous beneficiaries in Canada.
- University Health Network (UHN) — Toronto (Provincial multicenter study)coreA provincial multicenter study led by UHN is generating the clinical evidence needed to validate the systemic benefits of FASTRAX and support its future integration across the health system.
Scale indicators7 records
Recent moves8 records
Expansion highlights5 records
UCB Canada competitors and assessment
Company assessmentBroad incumbents
- AstraZeneca Canada: Canadian arm of AstraZeneca with Saphnelo, Fasenra, and rare disease assets (Alexion). Comparable through Canadian specialty pharma operations spanning immunology and rare disease, including neuromuscular rare disease overlap with UCB's gMG franchise.
- Amgen Canada: Canadian subsidiary of Amgen, marketing biologics across inflammation (Enbrel, Otezla, Tezspire), oncology, and rare disease. Comparable as a biologic-focused multinational pharma with Canadian operations engaging the same rheumatology and dermatology specialists as UCB Canada.
- Novartis Pharmaceuticals Canada: Canadian arm of Novartis selling Cosentyx (IL-17 inhibitor competing with BIMZELX), Kesimpta in neurology, and various specialty medicines. Highly comparable therapeutic overlap in immunology and neurology, and similar go-to-market through pCPA and provincial reimbursement.
- Roche Canada: Canadian subsidiary of Roche with Actemra, Ocrevus, and Hemlibra in neurology and immunology. Comparable therapeutic footprint across neurology and rare disease, including neuromuscular conditions adjacent to gMG.
- Eli Lilly Canada: Canadian arm of Eli Lilly with Taltz (IL-17 inhibitor directly competing with BIMZELX) in psoriasis, PsA, axSpA, plus Olumiant and emerging immunology assets. Highly comparable as a competitor in IL-17 class with Canadian commercial operations.
- Janssen Canada (Johnson & Johnson Innovative Medicine): Canadian pharmaceutical arm of J&J, marketing immunology biologics (Stelara, Tremfya, Remicade) and neurology assets. Directly comparable as a large multinational pharma with a Canadian subsidiary selling specialty biologics into the same rheumatology, dermatology, and gastroenterology channels as UCB Canada.
- Pfizer Canada: Canadian subsidiary of Pfizer with a broad specialty/biologic portfolio including Cibinqo, Xeljanz, and oncology assets. Comparable as a multinational pharma with Canadian operations selling specialty prescription medicines through similar reimbursement and HCP engagement channels.
- AbbVie Canada: Canadian subsidiary of AbbVie, the global leader in immunology with Humira, Skyrizi, and Rinvoq. Direct overlap with UCB Canada's immunology franchise (psoriasis, PsA, axSpA, HS) and competes head-to-head with CIMZIA and BIMZELX in the same specialist channels.
- Sanofi Canada (Sanofi Genzyme): Canadian arm of Sanofi with Dupixent (leading IL-4/13 inhibitor) in immunology/HS, and rare disease assets through Sanofi Genzyme. Direct overlap with UCB's HS franchise and similar patient identification and access programs in Canada.
Direct peers
- argenx Canada: argenx markets Vyvgart (efgartigimod), the first FcRn inhibitor approved for gMG in Canada, and competes head-to-head with UCB's RYSTIGGO in the same anti-FcRn class for AChR antibody-positive gMG patients. Closest direct competitor in the Canadian gMG market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
UCB Canada social profiles
Digital presenceUCB Canada financial estimates
Financial estimateRevenue estimate
Valuation estimate
UCB Canada leadership team
Management profileNumber of profiles
Profiles4 records
UCB Canada funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
UCB Canada M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about UCB Canada
What does UCB Canada do?
UCB Canada develops, manufactures, and commercializes prescription biopharmaceutical medicines in Canada, focused on immunology (psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, hidradenitis suppurativa, rheumatoid arthritis), neurology (epilepsy, Parkinson's disease), and rare diseases (generalized myasthenia gravis). The company also operates patient support programs (UCB Cares, UCB Connects, RxHelp ONE, ONWARD) and the FASTRAX Canada diagnostic innovation program for axial spondyloarthritis.
Is UCB Canada a public or private company?
UCB Canada is a private company. It is classified as corporate owned and is currently operating.
When was UCB Canada founded?
UCB Canada was founded in 2006. It employs 11 to 50 people.
Where is UCB Canada based?
UCB Canada is headquartered in Belleville, Canada, in the North America region.
How does UCB Canada make money?
One revenue line is on record: pharmaceutical product sales.
Who are UCB Canada's main competitors?
Broad incumbents on record are AstraZeneca Canada, Amgen Canada, Novartis Pharmaceuticals Canada, Roche Canada, Eli Lilly Canada, Janssen Canada (Johnson & Johnson Innovative Medicine), Pfizer Canada, AbbVie Canada and Sanofi Canada (Sanofi Genzyme). argenx Canada is listed as a direct peer.
Does UCB Canada have an API?
No public API is recorded for UCB Canada.
What industry is UCB Canada in?
UCB Canada's product category is Biopharmaceutical Medicines. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 8090.